EA201390339A1 - Замещенные имидазопиридазины - Google Patents

Замещенные имидазопиридазины

Info

Publication number
EA201390339A1
EA201390339A1 EA201390339A EA201390339A EA201390339A1 EA 201390339 A1 EA201390339 A1 EA 201390339A1 EA 201390339 A EA201390339 A EA 201390339A EA 201390339 A EA201390339 A EA 201390339A EA 201390339 A1 EA201390339 A1 EA 201390339A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
substituted
imidazopiridazines
pharmaceutical compositions
meanings
Prior art date
Application number
EA201390339A
Other languages
English (en)
Other versions
EA023420B1 (ru
Inventor
Ульрих Клар
Маркус Коппитц
Рольф Яутелат
Дирк Коземунд
Рольф Больманн
Филипп Линау
Герхард Зимайстер
Антье Маргрет Венгнер
Original Assignee
Байер Интеллектуэль Проперти Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Интеллектуэль Проперти Гмбх filed Critical Байер Интеллектуэль Проперти Гмбх
Publication of EA201390339A1 publication Critical patent/EA201390339A1/ru
Publication of EA023420B1 publication Critical patent/EA023420B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Paper (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение касается замещенных соединений имидазопиридазина общей формулы Iв которой R, Rи А имеют значения, как определено в формуле изобретения, способов приготовления указанных соединений, фармацевтических композиций и комбинаций, содержащих указанные соединения, и применения указанных соединений для производства фармацевтических композиций для лечения или профилактики заболевания, в частности гиперпролиферативного и/или ангиогенного нарушения, в качестве единственного средства или в комбинации с другими активными ингредиентами.
EA201390339A 2010-09-10 2011-09-06 Замещенные имидазопиридазины EA023420B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP11075022 2011-02-04
EP11170775 2011-06-21
EP11170771 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (2)

Publication Number Publication Date
EA201390339A1 true EA201390339A1 (ru) 2013-09-30
EA023420B1 EA023420B1 (ru) 2016-06-30

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390339A EA023420B1 (ru) 2010-09-10 2011-09-06 Замещенные имидазопиридазины

Country Status (38)

Country Link
US (1) US9255100B2 (ru)
EP (1) EP2614063B1 (ru)
JP (1) JP5824050B2 (ru)
KR (1) KR20140032337A (ru)
CN (1) CN103370318B (ru)
AP (1) AP3607A (ru)
AR (1) AR082946A1 (ru)
AU (1) AU2011298844B2 (ru)
BR (1) BR112013005679A2 (ru)
CA (1) CA2810755A1 (ru)
CO (1) CO6720961A2 (ru)
CR (1) CR20130102A (ru)
CU (1) CU24187B1 (ru)
CY (1) CY1117352T1 (ru)
DK (1) DK2614063T3 (ru)
DO (1) DOP2013000054A (ru)
EA (1) EA023420B1 (ru)
EC (1) ECSP13012752A (ru)
ES (1) ES2568220T3 (ru)
HK (1) HK1187623A1 (ru)
HR (1) HRP20160360T1 (ru)
HU (1) HUE028771T2 (ru)
IL (1) IL225058A (ru)
MA (1) MA34516B1 (ru)
ME (1) ME02389B (ru)
MX (1) MX2013002713A (ru)
MY (1) MY185139A (ru)
NZ (1) NZ607904A (ru)
PE (1) PE20131164A1 (ru)
PL (1) PL2614063T3 (ru)
RS (1) RS54661B1 (ru)
SA (1) SA111320735B1 (ru)
SG (1) SG188417A1 (ru)
SI (1) SI2614063T1 (ru)
TW (1) TWI541243B (ru)
UY (1) UY33598A (ru)
WO (1) WO2012032031A1 (ru)
ZA (1) ZA201301756B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
CA2889919C (en) * 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
PE20160156A1 (es) 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
MX2015017245A (es) * 2013-06-13 2016-07-20 Bayer Pharma AG Combinacion de un derivado de imidazopiridazina y un agente mitotico para el tratamiento del cancer.
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US10016398B2 (en) * 2014-02-21 2018-07-10 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR20180011089A (ko) 2015-04-17 2018-01-31 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이. Ttk 억제제 화학요법을 위한 예후 바이오마커
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
RU2721569C2 (ru) * 2015-12-04 2020-05-20 ЭкссонМобил Рисерч энд Энджиниринг Компани EMM-28 - новый синтетический кристаллический материал, его получение и применение
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
SI3484888T1 (sl) 2016-07-18 2023-07-31 University Health Network Trdne oblike inhibitorja ttk
CN110753560B (zh) * 2017-04-11 2022-07-26 斯特劳曼控股公司 牙科植入物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
KR20210146290A (ko) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2022415783A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263566C (en) 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
EA010023B1 (ru) 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1945644A2 (en) * 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
CN101687873A (zh) * 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
CN101981033B (zh) 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8729082B2 (en) 2009-04-29 2014-05-20 Bayer Intellectual Property Gmbh Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2793279A1 (en) 2010-03-18 2011-09-22 Ulrich Klar Imidazopyrazines
EP2576560B1 (en) 2010-06-01 2015-09-30 Bayer Intellectual Property GmbH Substituted imidazopyrazines
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2651944B1 (en) 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821819A1 (en) 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪

Also Published As

Publication number Publication date
US9255100B2 (en) 2016-02-09
DK2614063T3 (en) 2016-04-18
WO2012032031A1 (en) 2012-03-15
EA023420B1 (ru) 2016-06-30
US20130338133A1 (en) 2013-12-19
TWI541243B (zh) 2016-07-11
ECSP13012752A (es) 2014-01-31
CU24187B1 (es) 2016-07-29
ES2568220T3 (es) 2016-04-28
BR112013005679A2 (pt) 2016-05-03
JP2013537174A (ja) 2013-09-30
CU20130033A7 (es) 2013-08-29
AP2013006790A0 (en) 2013-04-30
CN103370318A (zh) 2013-10-23
AR082946A1 (es) 2013-01-23
CA2810755A1 (en) 2012-03-15
HUE028771T2 (en) 2016-12-28
HK1187623A1 (zh) 2014-04-11
AP3607A (en) 2016-02-26
MY185139A (en) 2021-04-30
CN103370318B (zh) 2016-04-20
RS54661B1 (en) 2016-08-31
CO6720961A2 (es) 2013-07-31
SA111320735B1 (ar) 2015-10-21
AU2011298844B2 (en) 2015-02-19
MX2013002713A (es) 2013-05-22
PE20131164A1 (es) 2013-10-30
AU2011298844A1 (en) 2013-03-28
TW201211049A (en) 2012-03-16
KR20140032337A (ko) 2014-03-14
PL2614063T3 (pl) 2016-06-30
EP2614063A1 (en) 2013-07-17
JP5824050B2 (ja) 2015-11-25
EP2614063B1 (en) 2016-01-13
DOP2013000054A (es) 2013-07-31
NZ607904A (en) 2015-02-27
SG188417A1 (en) 2013-04-30
CY1117352T1 (el) 2017-04-26
CR20130102A (es) 2013-04-17
ZA201301756B (en) 2016-06-29
UY33598A (es) 2012-04-30
MA34516B1 (fr) 2013-09-02
ME02389B (me) 2016-09-20
SI2614063T1 (sl) 2016-05-31
IL225058A (en) 2017-03-30
HRP20160360T1 (hr) 2016-05-06

Similar Documents

Publication Publication Date Title
EA201390339A1 (ru) Замещенные имидазопиридазины
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
EA201290919A1 (ru) Индазольные соединения и их применение
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201490407A1 (ru) Содержащие гидразид модуляторы нуклеарного транспорта и их применения
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201590693A1 (ru) Ингибиторы gdf-8
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
EA202190619A1 (ru) Противовирусные соединения
EA201200904A1 (ru) Противопаразитарные дигидроазоловые соединения и содержащие их композиции
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ TM RU